Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development
The derivation of human pluripotent stem cell (iPSC) lines by in vitro reprogramming of somatic cells revolutionized research: iPSCs have been used for disease modeling, drug screening and regenerative medicine for many disorders, especially when combined with cutting-edge genome editing technologies. In hematology, malignant transformation is often a multi-step process, that starts with either germline or acquired genetic alteration, followed by progressive acquisition of mutations combined with the selection of one or more pre-existing clones. iPSCs are an excellent model to study the cooperation between different genetic alterations and to test relevant therapeutic drugs. In this review, we will describe the use of iPSCs for pathophysiological studies and drug testing in inherited and acquired hematological malignancies. Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
|Authors||Donada A, Basso-Valentina F, Arkoun B, Monte-Mor B, Plo I, Raslova H|
|Journal||Stem cell research|
|Publication Date||2020 Oct 24;49:102060|